Neurotech Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesBlood & Organ Banks · Rhode Island, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
900 Highland Corporate Dr Ste 101, Cumbe...Phone Number
(401) 333-3880Revenue
<$5 MillionIndustry
About Neurotech Pharmaceuticals
Neurotech Pharmaceuticals is a private biotech company focused on developing transformative therapies for chronic eye diseases, specifically targeting Macular Telangiectasia (MacTel) Type 2. They offer MacTel treatment solutions, clinical trials, and their proprietary Encapsulated Cell Therapy (ECT) platform, which releases Ciliary Neurotrophic Factor (CNTF) to protect against photoreceptor loss. Their intended clients include healthcare professionals and patients suffering from MacTel, who experience gradual loss of central vision. The company is committed to advancing innovative treatments and has received FDA approval for their product ENCELTO.Explore more
Neurotech Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Neurotech Pharmaceuticals
Compare insights from companies similar to Neurotech Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Neurotech Pharmaceuticals Tech Stack
A closer look at the technologies used by Neurotech Pharmaceuticals
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neurotech Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Neurotech Pharmaceuticals is a private biotech company focused on developing transformative therapies for chronic eye diseases, specifically targeting Macular Telangiectasia (MacTel) Type 2. They offer MacTel treatment solutions, clinical trials, and their proprietary Encapsulated Cell Therapy (ECT) platform, which releases Ciliary Neurotrophic Fac... Read More
